Global Radiation Proctitis Treatment Market Is Expected To Progress At A Healthy CAGR Of Around 7% From 2022 To 2031

The global radiation proctitis treatment market is expected to progress at a healthy CAGR of around 7% from 2021 to 2031. Demand for acute radiation proctitis treatment is high, while over the coming years, the need for chronic radiation proctitis treatment is expected to increase significantly.

To remain ‘ahead’ of your competitors, request a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=5281

Will High Cost of Hyperbaric Oxygen Therapy Restrain Market Growth?

Cost is one of the major factors that influences the selection of treatment. Hyperbaric oxygen therapy is one of the few treatments for patients with severe radiation-induced symptoms, which include proctitis and cystitis with bleeding.

Currently, hyperbaric oxygen therapy is expensive, and therefore, low- and middle-income patients are unable to afford it, despite significant therapeutic effects. This might act as a major restraint for the growth of the radiation proctitis treatment sector.

Speak To Research Analyst For Detailed Insights: https://www.factmr.com/connectus/sample?flag=AE&rep_id=5281

Key Market Segments

  • Indication
    • Acute Radiation Proctitis
    • Chronic Radiation Proctitis
  • Therapy
    • Oral Therapy
      • Antidiarrheal
      • Anti-inflammatory Agents
      • Others
    • Ablative Procedures
    • Hyperbaric Oxygen Therapy
    • Formalin
    • Surgery
  • Region
    • North America (US and Canada)
    • Latin America (Brazil, Mexico and Rest of LATAM)
    • Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
    • Asia-Pacific (Japan, China, India, Australia & New Zealand and Rest of APAC)
    • Middle East & Africa (GCC, South Africa and Rest of MEA)

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=5281

Category-wise Insights

How is Chronic Radiation Proctitis (CRP) Treatment Fueling Market Expansion?

Although treatment for acute radiation proctitis remained dominant, attributed to a high prevalence rate (20%), chronic radiation proctitis treatment is anticipated to witness significant momentum in the forthcoming decade. While acute side effects manifest up to 3 months post treatment, chronic ones usually occur 3-6 months, or even years later post radiation therapy.

Medical therapy involving use of high amifostine and sucralfate has proven to be quite effective in imparting a protective barrier against the early and late short-term effects of radiation therapy. Moreover, research has concluded that use of synbiotics and microbiotics can be used to manipulate intestinal flora to prevent and treat CRP. Sun Pharmaceutical Industries is amongst the leading manufacturers of amifostine drug candidates.

Why is Oral Therapy Radiation Proctitis Treatment Expected to Remain the Most Preferred?

By treatment, oral radiation proctitis therapy is expected to remain dominant, attributed to its non-invasive nature. Amongst all oral treatment option, anti-inflammatory drugs consumption is expected to be the most widespread. Sulfasalazine, balsalazide and mesalazine are some important anti-inflammatory drugs deployed to treat radiation proctitis.

A number of regional level manufacturers offering anti-inflammatory treatment. These include Valens Molecules (sulphasalazine), PharmaZell (balsalazide), Surya Life Sciences (mesalazine), Jiangsu RUIKE (sulphasalazine), Corden Pharma (sulphasalazine) and BEC Chemicals (mesalazine) to name a few. These ingredients prove highly effective in scavenging oxygen radicals and inhibition of bacterial flora.

Read More Trending Reports of Fact.MR- https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/ 

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis 2016 – 2020 and Opportunity Assessment 2021 – 2031

About Us:

Fact.MR research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: sales@factmr.com

Visit Our Website: https://www.factmr.com

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2022 The Tribune City - Theme by WPEnjoy · Powered by WordPress